Desenvolvimento em VHDL da camada física de um transmissor 4G

The LTE and LTE-Advanced technologies are standards to the fourth mobile generation, or 4G. The planned successor of this mobile generation is 5G, which will be based on 5G-New Radio (5G-NR) standard. The 5G technology is on an initial phase of deployment. One of its features that are essential in this initial phase is the support for 4G communications, because many of the mobile devices currently in use do not have support for 5G communications. This support is made possible if there is an implementation where 4G and 5G networks both coexist with each other. In the future, with the increasing usage of mobile devices with 5G support, there will be a gradual migration of 4G networks to 5G, releasing frequency spectrums currently reserved for 4G so that those can be occupied by 5G. The data transmissions in 4G require quite a lot of the processing capacity of all systems within the mobile network. For 5G, the data transmissions, in terms of traffic volume and speed, are larger than 4G transmissions, requiring new systems to be implemented, to allow the processing of larger quantities of data. Implementation in hardware of a 4G Uplink transmission chain, at the physical layer level PHY-Low, will allow the optimization of certain processes that a CPU could handle, reducing CPU usage and time spent on processing. The use of FPGAs makes this possible, as FPGAs can perform parallel tasks simultaneously and perform digital signal processing. The purpose of this dissertation is the modelling of a 4G LTE Uplink transmitter, at the physical layer level. Then, synthesizable VHDL code is generated from the modeled system, which can be eventually implemented in FPGAs. The modelling of the system is made in Simulink, a tool inside the MATLAB software, which allows for modelling, simulating and analyzing systems in a graphic environment and has applications in control systems and digital signal processing. The VHDL code is generated from HDL Coder, another tool in MATLAB software, generating synthesizable Verilog and VHDL code, from the MATLAB functions and Simulink models. The results obtained of processed data from the system are analyzed and validated, comparing the reference data generated from Wireless Waveform Generator toolbox in MATLAB.A tecnologia LTE e LTE-Advanced são standards da quarta geração de comunicações moveis atuais, ou 4G. Futuramente, o 5G marca a próxima geração de comunicações moveis, segundo o standard 5G-New Radio (5GNR). A tecnologia 5G encontra-se numa fase inicial de implementação, sendo que nessa fase uma das suas características fundamentais é o suporte para comunicações 4G, pois muitos dos dispositivos moveis usados atualmente não possuem suporte para comunicações 5G. Este suporte para 4G é tornado possível, se for feita uma implementação onde as redes 4G e 5G se encontrem em coexistência. No futuro, com o aumento do uso de dispositivos moveis com suporte para 5G, haverá uma migração gradual de redes 4G para 5G, libertando os espectros de frequências reservados atualmente para o 4G para serem ocupados pelo 5G. As transmissões de dados no 4G exigem bastante da capacidade de processamento de todos os sistemas da rede movel. Para o 5G, as transmissões de dados tem volumes de tráfego e velocidades maiores do que as transmissões de dados 4G, fazendo com que novos sistemas tenham de ser implementados para poder processar maiores quantidades de dados. A implementação em hardware da cadeia de transmissão 4G Uplink, ao nível da camada física PHY-Low, permitirá a otimização de certos processos que um CPU poderia lidar, diminuindo o uso do CPU e o tempo gasto em processamento. O uso de FPGAs torna isto possível, tendo em conta que podem realizar tarefas em paralelo, em modo simultâneo, e fazer processamento digital de sinal. O objetivo desta dissertação assenta na modelação de um transmissor 4G LTE Uplink, ao nível da camada física. Depois, é gerado código VHDL sintetizável a partir do sistema modelado, que eventualmente será implementada em FPGAs. A modelação do sistema é feito em Simulink, uma ferramenta no software do MATLAB, que permite modelar, simular e analisar sistemas num ambiente gráfico e tem aplicações para sistemas de controlo e processamento digital de sinal. O código VHDL é gerado a partir do HDL Coder, uma outra ferramenta no software do MATLAB, que gera Verilog e VHDL sintetizáveis, a partir de funções MATLAB e de modelos Simulink. Os resultados obtidos dos dados processados pelo sistema são analisados e validados, comparando com os dados de referência obtidos a partir da toolbox Wireless Waveform Generator do MATLAB.Mestrado em Engenharia Eletrónica e Telecomunicaçõe

ASSOCIAÇÃO DO CARCINOMA PAPILÍFERO DE TIREÓIDE E TIREOIDITE DE HASHIMOTO

RESUMO: Este relato de caso pretende mostrar a relação entre Carcinoma Papilar da Tireóide (CPT) e Tireoidite de Hashimoto (TH) ocorrendo em uma mulher jovem, uma vez que representam os tipos de tumor mais comuns da tireóide e as principais causas de hipotireoidismo respectivamente e ambos são de ocorrência mais comum em mulheres. Acredita-se que haja um background genético comum em relação ao CPT e a TH. Levanta-se a questão acerca da necessidade de atenção no manejo de pacientes com TH.ASSOCIATION OF PAPILLARY THYROID CARCINOMA AND HASHIMOTOThis case report intents to show the relationship between Papillary Thyroid Carcinoma (PTC) and Hashimoto’s Thyroiditis (HT) occurring in a young woman as they are the most common neoplasm and the main cause for hypothyroidism respectively and both are more commonly to occur in women. It is believed that there is a genetic background concerned to PTC and HT. It issues the need of attention while managing patients with HT.Keywords: Hashimoto’s thyroiditis. papillary thyroid carcinoma. Thyroid

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

DIFICULDADES INICIAIS COM A TÉCNICA DA AMAMENTAÇÃO E FATORES ASSOCIADOS A PROBLEMAS COM A MAMA EM PUÉRPERAS

RESUMO Objetivo: Identificar a prevalência de condições indicativas de dificuldades iniciais com a técnica da amamentação e verificar os fatores associados com a presença de problemas na mama em puérperaso em maternidades de Hospitais Amigos da Criança. Métodos: Estudo transversal, conduzido com 276 binômios mãe-lactente, aleatoriamente selecionados entre os atendimentos realizados em maternidades de três Hospitais Amigos da Criança do norte de Minas Gerais. Um protocolo de avaliação da técnica da mamada foi utilizado como instrumento. A associação entre as variáveis estudadas e os problemas com a mama foi identificada por meio do teste qui-quadrado, seguida de análise de regressão logística, admitindo-se o nível de significância de até 5% (p<0,05). Resultados: Os principais fatores indicativos de dificuldades iniciais com a técnica da amamentação foram a pega inadequada (25,0%), a resposta do bebê ao contato com a mama (26,1%) e os problemas com a mama (28,3%). No modelo final de regressão múltipla, associaram-se aos problemas na mama no puerpério imediato: mãe adolescente (OR 3,35; IC95% 1,51-7,44; p=0,003); escolaridade ≤8 anos (OR 2,07; IC95% 1,01-4,23; p=0,048); e o fato de ter recebido complemento alimentar na maternidade (OR 2,36; IC95% 1,40-4,92; p=0,003). O fato de trabalhar fora de casa (OR 0,31; IC95% 0,16-0,61; p=0,001) foi um fator de proteção no modelo final de regressão logística. Conclusões: Problemas com as mamas representaram a principal dificuldade inicial com a técnica da mamada e os fatores associados incluem variáveis demográficas e sociais ligadas à mãe e variáveis relacionadas às rotinas da maternidade

FATORES ESTRESSORES ENTRE PROFISSIONAIS QUE ATUAM NO PRONTO-SOCORRO

Objetivo: descrever os fatores estressores entre os profissionais que atuam no pronto-socorro hospitalar. Métodos: trata-se de um estudo de revisão integrativa de literatura conduzido a partir das bases de dados secundários Scielo, Literatura Latino-Americana e do Caribe em Ciências da Saúde, Scientific Electronic Library Online e Site Motor de Busca Medical Database por meio dos descritores esgotamento profissional; estresse psicológico e profissionais de saúde. Resultados: constatou-se que há um número razoável de publicações de artigos referentes a síndrome de burnout e o nível de estresse voltado a equipe de saúde, sendo assim a amostra inicial foi de 120 artigos, porém 19 destes obedeciam aos critérios de inclusão e 15 desobedeciam apenas ao critério de inclusão em relação ao tempo de publicação, porém foram aproveitados, devido à escassez de material e por ter conteúdo pertinente. Conclusão: as características singulares do setor de pronto-socorro os quais, incluem: assistência prestada ao paciente, atender as emergências da unidade, lidar com a morte do paciente e com os familiares do paciente crítico estão relacionados a níveis significativos de estresse entre os profissionais